Published in Mol Cancer on June 03, 2010
NF-κB as potential target in the treatment of melanoma. J Transl Med (2012) 1.14
Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy. Chin Med (2011) 1.03
Curcumin: a potential candidate in prevention of cancer via modulation of molecular pathways. Biomed Res Int (2014) 0.94
Botanicals for the prevention and treatment of cutaneous melanoma. Pigment Cell Melanoma Res (2011) 0.85
4-Substituted-2-Methoxyphenol: Suitable Building Block to Prepare New Bioactive Natural-like Hydroxylated Biphenyls. Lett Drug Des Discov (2015) 0.81
Molecular changes induced by the curcumin analogue D6 in human melanoma cells. Mol Cancer (2013) 0.79
Curcuma Contra Cancer? Curcumin and Hodgkin's Lymphoma. Cancer Growth Metastasis (2013) 0.78
Phytochemicals for the Management of Melanoma. Mini Rev Med Chem (2016) 0.77
Protein expression changes induced in a malignant melanoma cell line by the curcumin analogue compound D6. BMC Cancer (2016) 0.75
Mitochondria and apoptosis. Science (1998) 23.41
Caspases: enemies within. Science (1998) 19.45
Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res (2003) 5.72
Aberrant rel/nfkb genes and activity in human cancer. Oncogene (1999) 5.62
Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene (1999) 4.76
The role of apoptosis in cancer development and treatment response. Nat Rev Cancer (2005) 4.19
Curcumin: the story so far. Eur J Cancer (2005) 4.17
Pharmacology of Curcuma longa. Planta Med (1991) 3.59
Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett (2008) 3.14
Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res (2009) 2.98
Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res (2001) 2.69
Quantification of cells cultured on 96-well plates. Anal Biochem (1989) 2.66
Curcumin: getting back to the roots. Ann N Y Acad Sci (2005) 2.42
Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg Med Chem (2008) 2.03
Role of curcumin in cancer therapy. Curr Probl Cancer (2007) 2.00
Cutaneous malignant melanoma. Mayo Clin Proc (2006) 1.88
Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis (2003) 1.64
Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp Cell Res (2001) 1.63
Induction of apoptosis by curcumin and its implications for cancer therapy. Curr Cancer Drug Targets (2005) 1.41
Neuroblastoma: biology and staging. Curr Oncol Rep (2009) 1.40
Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst (2006) 1.32
Trends in melanoma epidemiology suggest three different types of melanoma. Br J Dermatol (2007) 1.19
Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin Cancer Res (2008) 1.14
New therapeutic targets for the treatment of high-risk neuroblastoma. J Cell Biochem (2009) 1.14
X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. J Biol Chem (2009) 1.08
Melanoma incidence has risen in Europe. BMJ (2005) 1.06
Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells. Mol Cancer (2007) 0.98
Curcumin downregulates the constitutive activity of NF-kappaB and induces apoptosis in novel mouse melanoma cells. Melanoma Res (2007) 0.97
The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response. Clin Cancer Res (2009) 0.95
Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin. Oncogene (2005) 0.93
Molecular characterization and classification of neuroblastoma. Future Oncol (2009) 0.91
Therapeutic effects of the combination of fenretinide and all-trans-retinoic acid and of the two retinoids with cisplatin in a human ovarian carcinoma xenograft and in a cisplatin-resistant sub-line. Eur J Cancer (2000) 0.89
Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin. J Control Release (2007) 0.86
Differential solubility of curcuminoids in serum and albumin solutions: implications for analytical and therapeutic applications. BMC Biotechnol (2008) 0.83
Ligand-targeted liposomal therapies of neuroblastoma. Curr Med Chem (2007) 0.80
Pyrazoloacridine is active in multidrug-resistant neuroblastoma cell lines with nonfunctional p53. Clin Cancer Res (2003) 0.79
Development of novel antiatherogenic biaryls: design, synthesis, and reactivity. J Med Chem (2008) 0.77
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res (2004) 2.82
Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med (2012) 2.58
BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol (2012) 2.41
Autoantibodies to inner ear and endothelial antigens in Cogan's syndrome. Lancet (2002) 2.15
The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00
Spot overlapping in two-dimensional maps: a serious problem ignored for much too long. Proteomics (2005) 1.79
Retracted Inhibition of nonneuronal alpha7-nicotinic receptor for lung cancer treatment. Am J Respir Crit Care Med (2009) 1.74
Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res (2003) 1.50
A novel Bim-BH3-derived Bcl-XL inhibitor: biochemical characterization, in vitro, in vivo and ex-vivo anti-leukemic activity. Cell Cycle (2008) 1.45
Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res (2003) 1.45
Distribution and significance of 14-3-3sigma, a novel myoepithelial marker, in normal, benign, and malignant breast tissue. J Pathol (2004) 1.41
Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res (2006) 1.37
Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. Blood (2005) 1.37
HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clin Immunol (2009) 1.35
Macrophages are alternatively activated in patients with endometriosis and required for growth and vascularization of lesions in a mouse model of disease. Am J Pathol (2009) 1.33
Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst (2006) 1.32
X-inactivation patch size in human female tissue confounds the assessment of tumor clonality. Proc Natl Acad Sci U S A (2003) 1.30
Prune cAMP phosphodiesterase binds nm23-H1 and promotes cancer metastasis. Cancer Cell (2004) 1.27
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother (2014) 1.23
The chemopreventive polyphenol Curcumin prevents hematogenous breast cancer metastases in immunodeficient mice. Cell Physiol Biochem (2007) 1.21
Targeted drug delivery and penetration into solid tumors. Med Res Rev (2011) 1.19
Fusarium culmorum: causal agent of foot and root rot and head blight on wheat. Mol Plant Pathol (2012) 1.17
BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland. Oncol Rep (2008) 1.16
Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin Cancer Res (2008) 1.14
Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Ann N Y Acad Sci (2004) 1.14
NF-κB as potential target in the treatment of melanoma. J Transl Med (2012) 1.14
Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies. Am J Pathol (2010) 1.14
Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res (2003) 1.12
Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience. Curr Drug Targets (2013) 1.12
The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. J Biol Chem (2012) 1.11
MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project. Int J Cancer (2014) 1.10
Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report. J Med Case Rep (2012) 1.09
A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett (2009) 1.08
Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors. Clin Cancer Res (2003) 1.08
Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice. Cancer Immunol Immunother (2007) 1.07
New halogenated phenylcoumarins as tyrosinase inhibitors. Bioorg Med Chem Lett (2011) 1.07
Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. Clin Cancer Res (2008) 1.06
Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis. Clin Cancer Res (2007) 1.05
Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switching. J Biol Chem (2010) 1.05
Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer. Cell Cycle (2013) 1.03
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med (2011) 1.02
A mouse model of pulmonary metastasis from spontaneous osteosarcoma monitored in vivo by Luciferase imaging. PLoS One (2008) 1.02
Expression and methylation of CASP8 in neuroblastoma: identification of a promoter region. Nat Med (2002) 1.02
Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. BMC Cancer (2009) 1.02
Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells. Cell Res (2011) 1.02
Angiogenesis in neuroblastoma. Ann N Y Acad Sci (2004) 1.02
Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression. PLoS One (2012) 1.01
Mechanisms of free-radical induction in relation to fenretinide-induced apoptosis of neuroblastoma. J Cell Biochem (2003) 1.01
Altered trichothecene biosynthesis in TRI6-silenced transformants of Fusarium culmorum influences the severity of crown and foot rot on durum wheat seedlings. Mol Plant Pathol (2011) 1.00
Mutually exclusive expression of DLX2 and DLX5/6 is associated with the metastatic potential of the human breast cancer cell line MDA-MB-231. BMC Cancer (2010) 1.00
Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. Clin Cancer Res (2003) 0.98
Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells. Mol Cancer (2007) 0.98
Natural agents targeting the alpha7-nicotinic-receptor in NSCLC: a promising prospective in anti-cancer drug development. Int J Cancer (2008) 0.98
Amniotic liquid derived stem cells as reservoir of secreted angiogenic factors capable of stimulating neo-arteriogenesis in an ischemic model. Biomaterials (2011) 0.98
Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. Melanoma Res (2005) 0.97
Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. J Transl Med (2012) 0.97
Bone turnover in wild type and pleiotrophin-transgenic mice housed for three months in the International Space Station (ISS). PLoS One (2012) 0.97
Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian patients with breast carcinoma through hospital-based screening. Cancer (2005) 0.97
Frizzled receptor 6 marks rare, highly tumourigenic stem-like cells in mouse and human neuroblastomas. Oncotarget (2011) 0.97
Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma. Mol Ther (2011) 0.96
Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy. Eur J Cancer (2006) 0.96
Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. J Control Release (2010) 0.96
Antiangiogenic strategies in neuroblastoma. Cancer Treat Rev (2004) 0.95
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med (2013) 0.95
The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response. Clin Cancer Res (2009) 0.95